Skip Navigation


JAC Advance Access originally published online on September 29, 2004
Journal of Antimicrobial Chemotherapy 2004 54(5):909-914; doi:10.1093/jac/dkh436
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/5/909    most recent
dkh436v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chami, F.
Right arrow Articles by Remmal, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chami, F.
Right arrow Articles by Remmal, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC vol.54 no.5 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved

Evaluation of carvacrol and eugenol as prophylaxis and treatment of vaginal candidiasis in an immunosuppressed rat model

F. Chami1, N. Chami1, S. Bennis1, J. Trouillas2 and A. Remmal1,*

1 Faculté des Sciences, Fès Laboratoire de Biotechnologie, BP 1796, Atlas FES, Morocco; 2 Faculté de Médecine Lyon-RTH Laennec, Laboratoire d'Histologie Embryologie Moléculaires, Université Claude Bernard Lyon I, Lyon, France

* Corresponding author. Tel: +212-61-53-23-98; Fax: +212-55-73-29-81; Email: adnaneremmal{at}hotmail.com

Objectives: Anticandidal activity of carvacrol and eugenol, the major phenolic components of oregano and clove essential oils, respectively, were tested in vivo.

Methods: Efficacy evaluation of carvacrol and eugenol in the prophylaxis and treatment of experimental vaginal candidiasis was performed in immunosuppressed rats. The anticandidal activity was analysed by microbiological and histological techniques and was compared with that of nystatin.

Results: Microbiologically, prophylactic treatment with carvacrol eradicated the vaginal fungal burden of infected rats, whereas eugenol reduced the number of colony counts of Candida albicans in vaginas of infected rats by 98.9% 10 days after inoculation. Therapeutic treatment for 7 consecutive days with carvacrol was able to eradicate the vaginal candidal burden in 7/9 of the infected rats and reduced the number of colony counts of C. albicans in vaginas of the two remaining rats by 98%. Treatment with eugenol completely cured 2/9 of the infected animals, but the 7/9 still infected showed an 84% reduction of colony counts of C. albicans in their vaginas. Histologically, in all treated rats, no Candida organisms were found in the lumina of the vagina; this was in contrast to control groups in which many yeasts, strongly stained with periodic acid-Schiff, were observed. The results obtained with nystatin used at 10-fold minimal inhibitory concentration confirm the validity of this model.

Conclusions: Carvacrol and eugenol could be considered as promising products in the treatment of vaginal candidiasis. This work is a preliminary contribution to the development of a new generation of efficient and natural antifungal agents for curative treatment and prophylaxis.

Keywords: anticandidal activity , experimental vaginitis , animal models , antifungals , essential oils


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Med MicrobiolHome page
A. Nostro, A. Marino, A. R. Blanco, L. Cellini, M. Di Giulio, F. Pizzimenti, A. S. Roccaro, and G. Bisignano
In vitro activity of carvacrol against staphylococcal preformed biofilm by liquid and vapour contact
J. Med. Microbiol., June 1, 2009; 58(6): 791 - 797.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.